[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-loss-surgical\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-loss-surgical":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,52,91,120,148,175,199,227,251,274,304,327,351],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100644540","phase-3-tranexamic-acid-to-reduce-blood-loss-after-varus-derotation-osteotomy-100644540",false,"NCT07672158","Tranexamic Acid to Reduce Blood Loss After Varus Derotation Osteotomy","Postoperative Continuous Intravenous Tranexamic Acid Infusion to Reduce Blood Loss in Non-Ambulatory Children With Cerebral Palsy Following Bilateral Bony Hip Reconstructive Surgery: A Phase III Parallel-Group Randomised Placebo-Controlled Trial","TABLO","Inclusion Criteria:\n\n* Children (aged 4 to 16 years)\n* Diagnosis of cerebral palsy (CP). CP is an umbrella term under which many specific diagnoses are captured, and the clinical team at the study institution operates a comprehensive referral network to ensure patients with any relevant diagnoses are included.\n* Gross Motor Function Classification System (GMFCS) levels IV and V, with substantial hip displacement (\\>40% migration percentage per Australian Hip Surveillance Guidelines (Wynter M, Gibson N, Kentish M, Love S, Thomason P, Willoughby K, et al. Australian hip surveillance guidelines for children with cerebral palsy 2014. Australian Academy of Cerebral Palsy and Developmental Medicine. 2014.)), who are on the waitlist for bilateral proximal femoral varus derotational osteotomy (VDRO) +\u002F- unilateral or bilateral pelvic osteotomy.\n\nExclusion Criteria:\n\n* Haematological disorder (defined as an active genetic or acquired bleeding disorder)\n* Known hypersensitivity to tranexamic acid (TXA)\n* Children with promyelocytic leukaemia being treated with oral tretinoin will be excluded from the trial because combination with TXA has resulted in fatal thrombotic complications\n* Known coagulation defect\n* Known renal disorder (moderate to severe as per study institution guidelines)","ALL","4 Years","16 Years",{"count":21,"type":22},52,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","TABLO (Tranexamic Acid to reduce Blood Loss after varus derotation Osteotomy) is a clinical trial of postoperative tranexamic acid vs placebo in non-ambulatory children with cerebral palsy (CP) undergoing reconstructive hip surgery.\n\nImproving surgical outcomes is a high priority in this patient population given the high risk of bleeding and the diminished capacity for these children to withstand substantial blood loss. Preliminary data from the study institution indicates that approximately one third of these patients receive transfusion of blood products in the postoperative period. There is growing evidence that hidden blood loss occurring in the postoperative period is substantial and can potentially be attenuated with the administration of Tranexamic Acid (TXA). However, trials on postoperative TXA have been carried out exclusively in adult surgical populations.",[28,29,30,31,32,33],"Cerebral Palsy","Hip Surgery Corrective","Tranexamic Acid Use","Blood Loss, Surgical","Paediatrics","Orthopedics",[28,35,36,37,38],"Hip surgery","Tranexamic Acid","Blood Loss","Orthopaedics","NOT_YET_RECRUITING","2026-06-23",{"date":42,"type":43},"2026-06-26","ACTUAL",{"date":45,"type":22},"2026-07",{"date":47,"type":22},"2029-04",{"name":49,"class":50},"Murdoch Childrens Research Institute","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":51},"100643446","phase-4-carbetocin-monotherapy-versus-carbetocin-plus-oxytocin-infusion-in-elective-cesarean-delivery-a-non-inferiority-trial-100643446","NCT07636421","Carbetocin Monotherapy Versus Carbetocin Plus Oxytocin Infusion in Elective Cesarean Delivery: A Non-Inferiority Trial","Comparative Efficacy of Carbetocin Monotherapy Versus Carbetocin With Supplemental Oxytocin Infusion in Maintaining Uterine Tone and Preventing Blood Loss in Elective Cesarean Delivery: A Randomized, Double-Blind, Non-Inferiority Controlled Trial","CARBOXY-RCT","Inclusion Criteria:\n\n* Adult women aged 18 to 45 years\n* Scheduled for elective non-emergency cesarean delivery\n* Spinal anesthesia planned and administered as the sole anesthetic technique\n* Singleton pregnancy at gestational age of 37 completed weeks or more\n* ASA physical status II\n* Preoperative hemoglobin of 9 g\u002FdL or more\n* Able to provide written informed consent in Arabic or English\n\nExclusion Criteria:\n\n* Emergency or crash cesarean delivery\n* Placenta previa, placenta accreta spectrum disorder, or other abnormal placentation\n* Known uterine anomalies likely to impair contractility including fibroids greater than 5 cm, bicornuate or unicornuate uterus\n* Grand multiparity defined as 5 or more previous deliveries\n* Multiple gestation including twins or higher order\n* Polyhydramnios defined as amniotic fluid index greater than 24 cm\n* Prior oxytocin augmentation in current pregnancy for more than 6 hours\n* Known hypersensitivity to carbetocin, oxytocin, or any formulation excipient\n* Severe preeclampsia, eclampsia, or HELLP syndrome\n* Cardiovascular disease including arrhythmia, valvular disease, cardiomyopathy, or ischemic heart disease\n* Known coagulopathy or thrombocytopenia with platelets less than 100 x 10\\^9\u002FL\n* Hepatic or renal impairment\n* Body mass index greater than 40 kg\u002Fm2 at time of delivery\n* Enrollment in another interventional clinical trial","FEMALE","18 Years","45 Years",{"count":64,"type":22},332,[66],"PHASE4","Background: Carbetocin is an established single-dose uterotonic agent for postpartum hemorrhage prophylaxis at elective cesarean delivery. Despite its proven efficacy, many clinicians routinely add a supplemental oxytocin infusion following carbetocin administration without evidence-based justification. Concurrent oxytocin receptor stimulation may be redundant, counterproductive through receptor desensitization, or incrementally beneficial - a mechanistic uncertainty that remains unresolved in the published literature.\n\nObjectives: To determine whether carbetocin monotherapy (100 micrograms IV bolus plus placebo infusion) is non-inferior to carbetocin plus supplemental oxytocin infusion (10 IU over 4 hours) in preventing the need for additional uterotonic agents within 24 hours of elective cesarean delivery.\n\nStudy Design: Prospective, randomized, double-blind, placebo-controlled, non-inferiority trial with an integrated pilot phase. Phase 1 (Pilot, n=60) establishes local feasibility and event rate. Phase 2 (Full trial, n=332) provides the definitive non-inferiority analysis.\n\nParticipants: Women aged 18-45 years undergoing elective cesarean delivery under spinal anesthesia at Qassim University Medical City, singleton pregnancy at or beyond 37 weeks, ASA physical status II, preoperative hemoglobin 9 g\u002FdL or more.\n\nInterventions: Group C (Monotherapy): Carbetocin 100 micrograms IV bolus plus placebo saline infusion 500 mL over 4 hours. Group C+O (Combination): Carbetocin 100 micrograms IV bolus plus oxytocin 10 IU in 500 mL saline over 4 hours.\n\nPrimary Outcome: Proportion of patients requiring at least one additional uterotonic agent within 24 hours of delivery.\n\nSecondary Outcomes: Quantitative intraoperative blood loss by gravimetric measurement; total 24-hour blood loss; actual blood loss by Gross formula; hemoglobin and hematocrit changes; uterine tone scores by verbal numerical rating scale (0-10) at 2, 5, and 10 minutes; incidence of postpartum hemorrhage; blood transfusion requirement; hemodynamic profiles; adverse effects.\n\nSample Size: 332 patients (166 per group), non-inferiority margin 10 percentage points, one-sided alpha 0.025, 80% power, estimated baseline event rate 10%, with 15% dropout allowance.",[69,70,71,31],"Postpartum Hemorrhage","Uterine Atony","Cesarean Section",[73,74,75,76,77,78,79,80,81],"Carbetocin","Oxytocin","Uterotonic","Elective Cesarean Delivery","Non-Inferiority Trial","Uterine Tone","Gravimetric Blood Loss","Obstetric Anesthesia","Spinal Anesthesia","2026-06-04",{"date":84,"type":43},"2026-06-09",{"date":86,"type":22},"2026-08",{"date":88,"type":22},"2028-08",{"name":90,"class":50},"Mansoura University",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":61,"enrollmentInfo":98,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":119},"100640805","quantra-qplus-in-pediatric-cardiovascular-procedures-100640805","NCT07597278","Quantra QPlus in Pediatric Cardiovascular Procedures","Evaluation of the Clinical Performance of the Quantra System With the QPlus Cartridge in Pediatric Patients Undergoing Cardiovascular Procedures","Inclusion Criteria:\n\n* Subject is \\\u003C18 years of age.\n* Subject is undergoing a cardiovascular procedure OR subject underwent cardiovascular surgery and presents with acute bleeding or suspected hypocoagulation\u002Fhypercoagulation in a post-surgical unit.\n* Subject's parent(s) or guardian(s) has signed an informed consent form. If required, subject has signed an assent form.\n\nExclusion Criteria:\n\n* Corrected gestational age \\\u003C37 weeks.\n* Subject is enrolled in a study that might confound the result of the proposed study.\n* Subject is affected by a condition that, in the opinion of the clinical team, may pose additional risks.",{"count":99,"type":22},160,"OBSERVATIONAL","This study will evaluate the performance of the Quantra System with the QPlus Cartridge in pediatric patients undergoing cardiovascular procedures.",[31],[104,105,106,107,108],"Viscoelastic testing","Quantra","QPlus Cartridge","Pediatric","Cardiovascular surgery","2026-05-15",{"date":111,"type":43},"2026-05-19",{"date":113,"type":22},"2026-09-25",{"date":115,"type":22},"2027-10-15",{"name":117,"class":118},"HemoSonics LLC","INDUSTRY",3,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":130,"briefSummary":132,"conditions":133,"keywords":134,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":51},"100188653","phase-1-phenylephrine-tumescence-for-hemostasis-in-surgery-for-burn-injury-100188653","NCT01731444","Phenylephrine Tumescence for Hemostasis in Surgery for Burn Injury","Phenylephrine Tumescence for Hemostasis in Surgery for Burn Injury - A Randomized Control Trial","Inclusion Criteria\n\na) Burn injury requiring debridement and grafting between 5-30% TBSA\n\nExclusion Criteria\n\n1. Head and neck, hand, foot, or genital burns\n2. On anticoagulants (except NSAIDs)\n3. On monoamine oxidase inhibitor or tricyclic antidepressant\n4. Coronary or peripheral vascular disease\n5. History of arrhythmias\n6. On a Beta-blocker\n7. History of vascular abnormality\n8. Hypertension","75 Years",{"count":129,"type":22},24,[131],"PHASE1","The standard of care for treatment of burn injury is to inject a solution of epinephrine under the skin of the injured site in order to reduce blood loss during skin grafting. This solution of epinephrine has been shown to have effects on the body outside the donor site. Some people have increases in heart rate and blood pressure. We will study the effect of a phenylephrine solution in place of an epinephrine solution to control blood loss. We think that phenylephrine will help decrease blood loss and not change blood pressure or heart rate.\n\nThe injured area will be injected under the skin and a skin graft will be taken in the same way as we usually do. The only change will be the use of phenylephrine in the solution instead of epinephrine.\n\nOur goal is to find whether or not phenylephrine or epinephrine solution results in a reduction of blood loss without affecting the rest of the body.",[31],[135,136,137],"blood loss","burn","hemostasis","RECRUITING","2026-05-11",{"date":141,"type":43},"2026-05-14",{"date":143,"type":43},"2014-12-01",{"date":145,"type":22},"2028-12-31",{"name":147,"class":50},"University of Manitoba",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":127,"enrollmentInfo":154,"targetDuration":4,"studyType":23,"phases":156,"briefSummary":158,"conditions":159,"keywords":160,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":51},"100565810","delivering-transcutaneous-auricular-neurostimulation-to-reduce-blood-loss-during-dialysis-av-graft-placement-procedures-100565810","NCT06647017","Delivering Transcutaneous Auricular Neurostimulation to Reduce Blood Loss During Dialysis AV Graft Placement Procedures","Inclusion Criteria:\n\n* Participant is undergoing a dialysis port placement procedure using synthetic graft\n* Participant is between 18 and 75 years of age\n* Participant is English proficient\n* Participant is able to provide informed consent and function at an intellectual level sufficient for study requirements\n\nExclusion Criteria:\n\n* Participant has a BMI ≥ 40\n* Participant is currently taking a platelet inhibitor medication\n* Participant has a history of epileptic seizures\n* Participant has a history of neurological diseases or traumatic brain injury\n* Participant has presence of devices, e.g., pacemakers, cochlear prosthesis, neurostimulators\n* Participant has abnormal ear anatomy or ear infection present\n* Person of childbearing age, not using adequate contraception as per investigator judgment or not willing to comply with contraception for the duration of the study\n* Person who is pregnant or lactating\n* Participant has any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial",{"count":155,"type":22},40,[157],"NA","The objective of this study is to determine if tAN therapy can reduce the volume of blood lost during dialysis AV graft placement procedures.",[31],[161,162,163,135,164,165],"auricular neurostimulation","vagus nerve stimulation","transcutaneous","transcutaneous auricular neurostimulation","tAN","2026-05-07",{"date":168,"type":43},"2026-05-08",{"date":170,"type":43},"2024-11-13",{"date":172,"type":22},"2026-11-15",{"name":174,"class":118},"University Surgical Vascular",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":51},"100328210","phase-3-tranexamic-acid-in-adult-spinal-deformity-surgery-100328210","NCT03553186","Tranexamic Acid in Adult Spinal Deformity Surgery","Topical Tranexamic Acid as a Adjunct to Intravenous Tranexamic Acid in Adult Spinal Deformity Surgery","Inclusion Criteria:\n\n* Age 18-80\n* Scheduled to undergo posterior long segment ( ≥ 5 levels) posterior spinal fusion for adult scoliosis or degenerative joint diseae\n* \\+ fusion to pelvis\n\nExclusion Criteria:\n\n* Surgical factors:\n\n  * Anterior Approach\n  * Presence or history of dural tear without repair as evidenced by pseudomeningocele on MRI imaging or by intraoperative exploration\n  * Patients donating autologous blood preoperatively\n\nPatient factors:\n\n* Diagnosis of renal (Cr\\>1.5 or CrCl \\\u003C30ml\u002Fmin) or hepatic insufficiency (AST, ALT 2x upper limit of normal)\n* Diagnosis of seizure disorder or prior seizure\n* History of thromboembolic events (CVA, TIA, DVT, PE) if within 1 year of surgery\n* Hypercoagulability (e.g. antiphospholipid syndrome)\n* History of coronary artery disease (stent, MI, +stress test) within 1 year of surgery\n* Atrial fibrillation\n* Concurrent anticoagulation therapy that cannot be discontinued within 3 days before surgery (Coumadin, plavix, LVX)\n* Concurrent anticoagulation with ASA 325 that cannot be discontinued 10 days before surgery\n* Bleeding disorder or abnormal preoperative coagulation profile (as identified by a preoperative platelet count of \\\u003C100,000\u002Fmm3, an international normalized ratio of \\>1.4, or a prolonged partial thromboplastin time \\>1.4 times normal)\n* Preexisting anemia \\\u003C10 g\u002FdL\n* Color blindness or disturbance of color vision\n* Leukemia or active cancer\n* Religious restrictions on blood transfusion\n* Pregnancy or women who are lactating\u002Fbreastfeeding","80 Years",{"count":184,"type":22},100,[25],"Posterior spinal surgery for adult deformity is associated with high incidence of blood loss and need for blood transfusion and intraoperative blood salvage, with associated increased cost and risk for perioperative complications. Tranexamic acid (TXA) is relatively inexpensive anti-fibrinolytic agent that has been proven effective for decreasing intraoperative blood loss in various surgical specialties. Intravenous TXA (ivTXA) is routinely used at our institution for adult spinal deformity cases. Meanwhile, topical TXA (tTXA) is an attractive alternative\u002Fadjunct to ivTXA used with good results in orthopedic arthroplasty and cardiac surgery. To the investigators' knowledge, no data exists in the literature on the use of tTXA in either adult or pediatric spinal deformity surgery. The goal of this study is to determine the role tTXA has an adjunct to ivTXA in decreasing perioperative blood loss, drainage, transfusion requirements and length of stay following adult deformity spine surgery.",[188,189,31],"Spinal Deformity","Degenerative Lumbar Spinal Stenosis","2026-04-23",{"date":192,"type":43},"2026-04-28",{"date":194,"type":43},"2018-07-11",{"date":196,"type":22},"2027-03",{"name":198,"class":50},"Hospital for Special Surgery, New York",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":23,"phases":209,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":226},"100615121","phase-3-phase-3-trial-of-vmx-c001-vs-usual-pharmacological-care-in-patients-taking-a-fxa-direct-oral-anticoagulant-who-require-urgent-surgery-with-or-without-heparin-100615121","NCT07288489","Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.","A Phase 3 Prospective Randomised Clinical Trial of VMX-C001 vs Usual Pharmacological Care in Patients Receiving a FXa Direct Oral Anticoagulant (FXa DOAC) Who Require Urgent Surgery or Other Invasive Procedure That is Associated With a High Risk of Bleeding, With or Without Planned Administration of Heparin (EQUILIBRIX-S)","EQUILIBRIX-S","Inclusion Criteria:\n\n1. Male or female patient aged ≥18 years.\n2. The patient or legally authorised representative (LAR) has given written informed consent.\n3. The patient requires urgent surgery\u002Fprocedure for which the risk of bleeding is considered high and for which haemostasis is considered necessary.\n4. The patient has a significant FXa DOAC level at the time of procedure.\n5. The patient would require treatment (usual pharmacological care) to restore coagulation for the required procedure.\n6. The patient must be willing to use appropriate contraception.\n\nExclusion Criteria:\n\n1. The patient is known for any reason, other than administration of a FXa DOAC, to have an increased risk of bleeding compared to a patient in a similar clinical situation.\n2. The patient has received any non FXa DOAC anticoagulants within 7 days of Screening or has received heparin (UFH or LMWH) within 3 days of Screening.\n3. The patient has received any of the prespecified medications not allowed in the 7 days prior to Randomisation.\n4. The patient was treated with an investigational drug \\\u003C30 days or 5 half-lives, whichever is longer, prior to Screening.\n5. Expected survival, in the Investigator's judgement, is \\\u003C3 months due to comorbidity.\n6. Patients in whom the Investigator considers it is not possible to estimate the expected blood loss.\n7. Known \"Do Not Resuscitate\" order or similar advanced directive.\n8. Cardiogenic shock at the time of screening unless related to the need for the required procedure.\n9. The patient has sepsis (including severe sepsis or septic shock) at the time of screening.\n10. The patient is pregnant or a lactating female.\n11. Known hypersensitivity to any component of VMX-C001 or hamster proteins.\n12. Patients who, in the opinion of the Investigator, should not participate in the study for any other reason, or inability to comply with the protocol.\n13. Prior exposure to VMX-C001.",{"count":208,"type":22},800,[25],"The goal of this clinical trial is to learn if VMX-C001 works to to allow blood clotting control in participants who take FXa Direct Oral Anticoagulants (DOACs) during surgery or other invasive procedures that carry a high risk of bleeding. The main question it aims to answer is:\n\n● What is the proportion of participants in whom the stopping of bleeding was classed as good or excellent during the procedure, as judged by a group of experts who did not know which treatment was given?\n\nResearchers will compare a fixed dose of VMX-C001 to the usual treatment that would be given for the required procedure.\n\nParticipants will:\n\n* Be given either a fixed dose of VMX-C001 or usual treatment before they undergo the required procedure in theatre\n* Have regular clinical assessments, including laboratory tests, during their hospital stay following the procedure\n* Return to the clinic for a check-up and tests approximately 28 days after the procedure was conducted.",[31,212],"Coagulation Disorder",[214,215,216],"Direct oral anticoagulant (DOAC)","Human coagulation factor","Surgery","2026-02-25",{"date":219,"type":43},"2026-02-27",{"date":221,"type":22},"2026-03",{"date":223,"type":22},"2031-01",{"name":225,"class":118},"VarmX B.V.",26,{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":60,"minAge":61,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":23,"phases":236,"briefSummary":238,"conditions":239,"keywords":241,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":249,"locationsCount":51},"100609693","phase-2-prophylactic-intravenous-calcium-gluconate-to-decrease-blood-loss-at-time-of-cesarean-delivery-in-pregnant-patients-at-high-risk-for-uterine-atony-100609693","NCT07217899","Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony","Phase II, Randomized, Double Blinded, Placebo Controlled Superiority Trial of Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony","Inclusion Criteria:\n\n* English speaking\n* Viable Intrauterine Pregnancy, Gestational Age ≥24 weeks\n* Labor Converted to Cesarean Delivery at High Risk for Atonic Bleeding Defined as: Any exposure to oxytocin infusion for labor augmentation or induction prior to cesarean delivery\n* Or Scheduled Cesarean Delivery at High Risk for Atonic Bleeding Defined as scheduled Cesarean-Section (CS) plus any one of:\n\n  1. \\> 4 Prior deliveries\n  2. General anesthesia\n  3. Multifetal gestation\n  4. Polyhydramnios diagnosed by ultrasound within 2 weeks\n  5. Macrosomia ≥ 4000gms; estimated fetal weight by palpation or by ultrasound\n  6. Fibroid uterus, defined as: Multiple ≥ 2cm intramural\n  7. Any history of prior Primary postpartum hemorrhage (PPH)\n  8. Platelets \\\u003C 100,000 (but \\>50,000\n  9. Placenta Previa\n  10. Body Mass Index (BMI) ≥ 40\n\nExclusion Criteria:\n\n* Non-English speaking\n* Antenatal suspicion for placenta accreta spectrum\n* History of allergic reaction to Calcium Gluconate\n* Patients with hypertensive disorder of pregnancy receiving Magnesium Sulfate for seizure prophylaxis\n* Underlying Renal Disease defined as Cr\\>1.0\n* Known underlying cardiac condition\n* Cardiac glycosides (Digoxin) within two weeks for maternal or fetal indication\n* Treatment with a calcium channel blocker medication within 24 hours of screening\n* Hypertensive disorder necessitating intravenous antihypertensive medication within 24 hours of screening\n* Emergent case where study participation could impede care (judgement of obstetrician or anesthesiologist)\n* Known hypercalcemia\n* Concurrent use of any drugs that may cause hypercalcemia including\n\n  1. Vitamin D\n  2. Vitamin A\n  3. Thiazide Diuretics\n  4. Calcipotriene\n  5. Teriparatide\n* Ceftriaxone within 48 hours of screening\n* Total Parenteral Nutrition (TPN) within 48 hours of screening\n* Known Coagulopathy International Normalized Ratio (INR) ≥ 1.5\n* Vaginal delivery",{"count":235,"type":22},140,[237],"PHASE2","This research study is being done to learn what effect a single dose of calcium gluconate will have on blood loss at the time of cesarean delivery in pregnancy patients at high risk for uterine atony.",[31,240,70],"Blood Loss, Postoperative",[242],"Cesarean delivery","2025-10-28",{"date":245,"type":43},"2025-10-29",{"date":247,"type":43},"2025-10-20",{"date":86,"type":22},{"name":250,"class":50},"University of Michigan",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":273},"100445183","safe-and-timely-antithrombotic-removal-star-registry-100445183","NCT05077124","Safe and Timely Antithrombotic Removal (STAR) Registry","Safe and Timely Antithrombotic Removal (STAR) Registry: International Registry on the Use of CytoSorb for Removal of Antithrombotic Agents in the Acute Hospital Setting","Inclusion Criteria:\n\n* CytoSorb utilization for antithrombotic removal\n* Informed consent for prospective registry participation\n\nExclusion Criteria:\n\n• Use of CytoSorb for purpose other than antithrombotic removal",{"count":259,"type":22},1000,"This registry will capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb for the removal of antithrombotic agents.",[262,263,31,240],"Hemorrhage, Surgical","Hemorrhage Postoperative","2025-07-15",{"date":266,"type":43},"2025-07-16",{"date":268,"type":43},"2021-09-30",{"date":270,"type":22},"2025-09-30",{"name":272,"class":118},"CytoSorbents, Inc",30,{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":284,"conditions":285,"keywords":291,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":300,"leadSponsor":302,"locationsCount":51},"100565050","patient-blood-management-in-patients-scheduled-for-cardiac-surgery-100565050","NCT06637137","Patient Blood Management in Patients Scheduled for Cardiac Surgery","Patient Blood Management in Cardiac Surgical Patients: the ICARUS-2 Study","ICARUS-2","Inclusion Criteria:\n\n\\- all adult patients scheduled for elective cardiac surgery\n\nExclusion Criteria:\n\n* pregnancy\n* dyalisis\n* patient's refusal",{"count":283,"type":22},464,"The ICARUS 2 study has the general objective of collecting data in patients undergoing cardiac surgery; in our centre, in order to optimize and improve hemoglobin values, a team of haematologists, assisted by cardio anesthetists and cardiac surgeons, will evaluate the blood tests of patients scheduled for elective cardiac surgery in order to correct any states of hypoferritinemia (low iron in the blood) to promote recovery from blood losses related to cardiac surgery. This objective is strongly encouraged by the good use of blood programs currently in force at our foundation.\n\nIn particular, the research presented here intends to demonstrate a reduction in the number of intra- and post-operative transfusions.",[286,287,288,289,290,31],"Anemia","Anemia, Iron-Deficiency","Iron Deficiency Anemia Treatment","Iron Deficiency Anemia (IDA)","Cardiac Surgical Patients",[292,293,294,295],"iron","anemia","cardiac surgery","patient blood management","2025-02-24",{"date":298,"type":43},"2025-02-26",{"date":296,"type":43},{"date":301,"type":22},"2027-02-28",{"name":303,"class":50},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":311,"sex":17,"minAge":61,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":23,"phases":315,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":323,"leadSponsor":325,"locationsCount":51},"100571859","early-phase-1-assessment-of-nebulized-tranexamic-acid-in-functional-endoscopic-sinus-surgery-using-modena-bleeding-score-100571859","NCT06725732","Assessment of Nebulized Tranexamic Acid in Functional Endoscopic Sinus Surgery Using Modena Bleeding Score","Assessment of Nebulized Tranexamic Acid in Functional Endoscopic Sinus Surgery Using Modena Bleeding Score. A Randomized Double Blinded Controlled Trial.","Inclusion Criteria:\n\n1. Either sex\n2. age 18-65 years\n3. ASA I-II who are listed for elective functional endoscopic sinus surgery (FESS) under general anesthesia\n4. normal accepted coagulation profile and hematocrit value ≥30\n\nExclusion Criteria:\n\n* • chronic renal failure\n\n  * liver cirrhosis\n  * bleeding disorders\n  * current anticoagulant therapy\n  * pregnancy or breastfeeding\n  * impaired color vision\n  * severe vascular ischemia\n  * history of venous thrombosis, pulmonary embolism\n  * long term treatment with acetylsalicylic acid or non-steroidal anti-inflammatory drugs not discontinued before surgery\n  * hemoglobin (HB) concentration \\\u003C10 mg\u002Fdl \\_allergy to TXA.\n  * BMI \\> 35 kg\u002F m2",true,"65 Years",{"count":314,"type":22},90,[316],"EARLY_PHASE1","The aim of this study is to investigate the effect of preoperative administration of intravenous or nebulized tranexamic acid on surgical field, blood loss, anesthetic consumption and hemodynamics of patients undergoing FESS.\n\nPrimary outcome Modena Bleeding Score (MBS) assessing surgical field Secondary outcome\n\n1. Patient hemodynamics.\n2. Anesthetic consumption, Extra doses of fentanyl and propofol and sevoflurane\\>2\n3. Postoperative complications: including any adverse effects to TXA e.g.nausea, vomiting, any visual disturbances, fits, and any thrombotic manifestation.",[31],"2025-01-27",{"date":321,"type":43},"2025-01-29",{"date":321,"type":22},{"date":324,"type":22},"2026-01-01",{"name":326,"class":50},"Assiut University",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":311,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":336,"briefSummary":337,"conditions":338,"keywords":340,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":51},"100562316","effectiveness-of-a-intraoperative-blood-recovery-system-in-cardiovascular-surgery-in-brazil-100562316","NCT06601582","Effectiveness of a Intraoperative Blood Recovery System in Cardiovascular Surgery in Brazil","Effectiveness of a Intraoperative Blood Recovery System in Cardiovascular Surgery Using Cardiopulmonary Bypass in Brazil. Randomized Crontrolled Trial","Inclusion Criteria:\n\n* all patients undergoing CABG or Valve surgery singly.\n\nExclusion Criteria:\n\n* Emergency cardiac surgery;\n* Previous heart surgery;\n* End-stage chronic kidney disease;\n* Inability to receive a blood transfusion (refusal);\n* Anemia (hemoglobin less than 10g\u002Fdl);\n* Thrombocytopenia (platelet count less than 100,000\u002Fmm3);\n* Coagulopathy (RNI \\> 1.5);",{"count":335,"type":22},60,[157],"Randomized trial to evaluate the effectiveness of a intra operative blood recovery system in reducing the need for allogeneic transfusion in cardiovascular surgeries using cardiopulmonary bypass",[339,31],"Cardiovascular Surgery",[339,341],"Operative Blood Salvage","2024-09-15",{"date":344,"type":43},"2024-09-19",{"date":346,"type":43},"2022-04-01",{"date":348,"type":22},"2024-12-31",{"name":350,"class":50},"Instituto Materno Infantil Prof. Fernando Figueira",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":60,"minAge":61,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":23,"phases":359,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":51},"100549028","phase-4-role-of-txa-in-patients-undergoing-breast-free-flap-reconstruction-100549028","NCT06428682","Role of TXA in Patients Undergoing Breast Free Flap Reconstruction","Role of Intravenous Tranexamic Acid Use in Patients Undergoing Breast Free Flap Reconstruction: Randomized Controlled Trial","Inclusion Criteria:\n\n* All female patients who are 18 years or older who will undergo unilateral or bilateral abdomen-based free flap breast reconstruction at UVA Medical Center\n\nExclusion Criteria:\n\n* Subjects with ages \\\u003C18 years\n* Allergy to TXA\n* Subjects who has contraindications to TXA: anyone who has active intravascular thrombosis or anyone with subarachnoid hemorrhage\n* Subjects who have anemia (defined as baseline hemoglobin \\\u003C8 g\u002FdL\n* Subjects who cannot read or understand English\n* Subjects who are pregnant",{"count":184,"type":22},[66],"Tranexamic acid (TXA) is a synthetic, competitive lysine receptor inhibitor on plasminogen. It ultimately stabilizes the fibrin matrix, therefore used as a hemostatic agent for various indications. While there has been indications for orthopedic and trauma surgery, there is no clear data for its role in patients who are undergoing free tissue transfer. Studies have shown that patients undergoing free tissue transfer can have transfusion rates ranging from 7.2% to 34.9%, which data also showing association between transfusion requirement and higher free flap failure rate. There has been a few retrospective studies that evaluated the effect of TXA in free tissue transfer and the results showed no increased risk of microanastomosis failure but some showing decreased blood loss. This study aims to further analyze the role of TXA in patients undergoing breast free flap reconstruction with randomized, prospective trial. Control group will not receive TXA while experimental group will receive TXA. Both groups will receive standard of care breast free flap surgery as well as post-op care, which is streamlined with Early Recovery After Surgery (ERAS) protocol. Their pre and post-op hemoglobin will be compared, as well as rates of transfusion, surgical outcome and surgical complications including hematoma, flap failure, and any other medical complications such as Deep Vein Thrombosis (DVT)\u002F Pulmonary Embolism (PE).",[362,31],"Breast Cancer",[364,365,36],"Autologous breast reconstruction","Free Flap","2024-06-03",{"date":368,"type":43},"2024-06-05",{"date":370,"type":43},"2024-05-13",{"date":372,"type":22},"2026-05-13",{"name":374,"class":50},"University of Virginia"]